Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit

As six companies have now settled with AbbVie over when they can launch their Humira (adalimumab) biosimilars in 2023, Germany-headquartered Boehringer Ingelheim continues to wrangle in court with the Chicago-based AbbVie.